Price to sales forward of Arcturus Therapeutics Holdings Inc. – NASDAQ:ARCT
This page displays the "Price to sales forward" metric for Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT). It indicates that the market for ARCT was closed and no trades were recorded, providing various financial, news, and community tabs for further research.
Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar?
Arcturus Therapeutics (ARCT) stock jumped 5.7% after the company announced a strategic collaboration with Thermo Fisher Scientific for the phase III development and commercialization of its cystic fibrosis mRNA therapy, ARCT-032. While the stock saw a significant gain, its near-term outlook is cautious, holding a Zacks Rank #3 (Hold), due to unchanged consensus EPS estimates for the upcoming quarter despite strong revenue and earnings expectations. The article suggests investors monitor future earnings estimate revisions to determine if the recent strength will continue.
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis
Arcturus Therapeutics announced a strategic collaboration with Thermo Fisher Scientific to advance its investigational mRNA therapy, ARCT-032, for Cystic Fibrosis. This partnership will leverage Thermo Fisher's Accelerator™ Drug Development solutions for integrated manufacturing, clinical research, and commercial readiness services, supporting ARCT-032's Phase 3 development and potential commercialization. The agreement includes provisions for exclusive commercial manufacturing rights for Thermo Fisher if ARCT-032 receives regulatory approval.
ARCT Initiates Coverage by Freedom Broker -- Rating Set to Buy
Freedom Broker has initiated coverage on Arcturus Therapeutics (ARCT) with a "Buy" rating and a price target of $27.00. Despite this positive analyst outlook, GuruFocus assesses ARCT as 65.8% overvalued with a GF Value™ of $4.15 compared to its current market price of $6.88. The company's GF Score™ of 56/100 suggests moderate potential for long-term returns, balanced by a fair Financial Strength rating but lower Profitability and Growth ranks.
Freedom Capital Markets Initiates Arcturus Therapeutics(ARCT.US) With Buy Rating, Announces Target Price $27
Freedom Capital Markets has initiated coverage on Arcturus Therapeutics (ARCT.US) with a Buy rating. The firm has set a target price of $27 for the biotechnology company. This initiation suggests a positive outlook on Arcturus Therapeutics' future performance.
ARCT - Arcturus Therapeutics Holdings Inc Latest SEC Filings
This article provides key financial data and performance metrics for Arcturus Therapeutics Holdings Inc. (ARCT), including its market capitalization, income, sales, per-share values, and various ratios. It also details the company's past and projected EPS and sales growth, insider and institutional ownership, and stock performance across different timeframes.
Price to earnings forward of Arcturus Therapeutics Holdings Inc. – NASDAQ:ARCT
The article presents a financial data point for Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) specifically focusing on its price-to-earnings forward ratio. The content appears to be a stub or a data visualization page from TradingView, indicating a value for this metric over a certain period.
Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell 2500 Growth Benchmark
Arcturus Therapeutics Holdings Inc. (NasdaqGM:ARCT) has been removed from the Russell 2500 Growth Benchmark, as announced on June 29, 2026. This news follows several other recent benchmark removals for the company, including from the Russell Small Cap Comp Growth, Russell 2000 Growth, Russell 3000E Growth, Russell Microcap Growth Benchmark Index, and Russell 3000 Growth benchmarks. Arcturus Therapeutics is a commercial mRNA medicines and vaccines company focusing on infectious disease vaccines and rare diseases.
Arcturus Therapeutics Holdings, Inc. Actuals & Estimates (NASDAQ:ARCT)
This article provides an overview of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), detailing its current stock price, historical performance, analyst forecasts, and financial data. It includes key financial metrics such as market capitalization, EBITDA, and recent earnings reports, alongside employee count and dividend policy. The article advises potential investors to conduct thorough research, offering technical analysis and suggesting relevant resources on TradingView.
ARCT Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Arcturus Therapeutics Holdings Inc. (ARCT) stock for 2027, based on analyst opinions. It includes current stock performance, historical highs and lows, market capitalization, volatility, and details on past and upcoming earnings reports, along with other financial statistics. The analysis also advises on conducting comprehensive research before investing.
Discipline and Rules-Based Execution in ARCT Response
This article analyzes Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) using AI models, highlighting a near-term strong sentiment potentially challenging persistent mid and long-term weakness. It identifies a mid-channel oscillation pattern and offers three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels, alongside multi-timeframe signal analysis. The report emphasizes a 212.5:1 risk-reward setup targeting a 78.1% gain versus a 0.4% risk.
Arcturus Therapeutics Holdings Inc (ARCT) Risk Assessment: Volatility, Financial Risk & Investment Risk
Arcturus Therapeutics Holdings Inc (ARCT) currently holds a risk assessment score of 2.19, ranking 233 out of 389 in the Biotechnology & Medical Research industry. The company's beta value of 2.37 suggests higher volatility compared to the S&P 500. The assessment includes detailed metrics on volatility, maximum drawdown, and return-to-drawdown ratios over various periods.
Arcturus Therapeutics Holdings Inc (ARCT) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Arcturus Therapeutics Holdings Inc (ARCT), listing major shareholders and their proportional holdings, including Federated Hermes Global Investment Management Corp., ARK Investment Management LLC, and BlackRock Institutional Trust Company, N.A. It also outlines the breakdown of shareholder types, such as investment advisors, hedge funds, and individual investors. Additionally, the report provides historical institutional shareholding data and recent changes in holdings by key investors, along with related ETF exposures.
ARCT SEC Filings - Arcturus Therape 10-K, 10-Q, 8-K Forms
This page provides comprehensive access to Arcturus Therapeutics (ARCT) SEC filings, including 10-K, 10-Q, and 8-K forms, along with insider trading information. It details a recent Q2 2025 earnings press release and a Schedule 13G/A filing from ARK Investment Management disclosing a significant stake in ARCT. The platform offers AI-generated summaries, impact scoring, and sentiment analysis for each filing.
Arcturus Therapeutics Holdings Inc
This article provides an overview of Arcturus Therapeutics Holdings Inc (ARCT), including its current stock price and market capitalization. It highlights that relevant data regarding the company's revenue breakdown by business segments and regional contribution have not been disclosed yet. The piece focuses on the lack of detailed financial segment information for ARCT.
Arcturus Therapeutics Holdings Inc (ARCT) Valuation: PE, PB & Fair Value Analysis
The article provides a valuation analysis for Arcturus Therapeutics Holdings Inc (ARCT), noting its current valuation score is 7.25, ranking 253 out of 388 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -2.60, which is significantly below its recent high and above its recent low. The article also states that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Arcturus Therapeutics Holdings Inc (ARCT) Earnings Forecast: Future EPS & Revenue Growth Estimates
Arcturus Therapeutics Holdings Inc (ARCT) has an earnings forecast score of 8.00, ranking 163 out of 388 in its industry, with an average analyst price target of $21.50. Analysts predominantly recommend a "Buy" for ARCT, with 12 analysts contributing to the rating. The company's expected revenue for the next quarter is $3.41 million, and EPS for the previous quarter was -$1.03, with the same expected for the upcoming quarter.
Arcturus Therapeutics (ARCT) director awarded 15,000 stock options at $7.30
Arcturus Therapeutics Holdings Inc. director John Markels was granted 15,000 stock options at an exercise price of $7.30 per share as part of his 2026 annual board compensation. These options, which expire on June 5, 2036, will vest monthly over one year from the grant date. Following this transaction, Markels directly holds stock options for 15,000 shares.
Arcturus (NASDAQ: ARCT) director receives 15,000 stock options as 2026 board grant
Arcturus Therapeutics Holdings Inc. director Moncef Slaoui was granted 15,000 stock options as part of his annual board compensation for 2026. These options, with an exercise price of $7.30 per share and an expiration date of June 5, 2036, will vest monthly over one year from the grant date. Following this grant, Slaoui directly holds 15,000 derivative securities.
Board member at Arcturus (NASDAQ: ARCT) receives 15,000 stock options
Arcturus Therapeutics Holdings Inc. director Magda Marquet was granted 15,000 stock options with an exercise price of $7.30 per share, expiring on June 5, 2036. These options vest monthly over one year and represent her 2026 annual grant as a Board member. The transaction indicates a neutral impact and sentiment according to Rhea-AI.
Arcturus (NASDAQ: ARCT) director receives 15,000 stock options as 2026 grant
Arcturus Therapeutics Holdings Inc. director Edward W. Holmes received a grant of 15,000 stock options as part of his 2026 annual board compensation. The options allow him to buy common stock at an exercise price of $7.30 per share and expire on June 5, 2036. These options will vest monthly over a one-year period from the grant date, and Holmes now holds 15,000 derivative securities.
Arcturus (ARCT) director Jing L. Marantz granted 15,000 stock options
Arcturus Therapeutics Holdings Inc. director Jing L. Marantz was granted 15,000 stock options at an exercise price of $7.30 per share, expiring on June 5, 2036. This grant represents her 2026 annual compensation for Board service, with the options vesting monthly over one year from the grant date. Following this award, Marantz directly holds stock options for 15,000 shares.
Director at Arcturus (NASDAQ: ARCT) receives 15,000 stock options grant
Arcturus Therapeutics Inc. director James F. Barlow was granted 15,000 stock options as part of his 2026 board compensation. These options allow him to buy common stock at an exercise price of $7.30 per share and will vest monthly over a one-year period, aligning his compensation with the company's performance. The options are set to expire in 2036.
Director Peter Farrell receives 15,000 Arcturus (NASDAQ: ARCT) stock options
Arcturus Therapeutics Holdings Inc. director Peter C. Farrell has been granted 15,000 stock options as part of his 2026 annual compensation for Board service. The options have an exercise price of $7.3000 per share, expire on June 5, 2036, and will vest monthly over one year from the grant date. This transaction was reported via a Form 4 SEC filing, indicating an equity-based compensation rather than an open-market purchase.
Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies
Arcturus Therapeutics presented its mRNA pipeline, including vaccine approvals and clinical milestones, at the Jefferies Global Healthcare Conference. The company emphasized its differentiated LUNAR delivery platform and manufacturing capabilities for therapeutic mRNA applications, particularly focusing on its cystic fibrosis program (ARCT-032) and ornithine transcarbamylase deficiency program (ARCT-810). Additionally, Arcturus highlighted its Kostaive COVID-19 vaccine, approved in 32 countries, and its H5N1 bird flu vaccine program with BARDA, showcasing its advancements in both prophylactic and therapeutic mRNA medicine.
Arcturus Therapeutics (ARCT) holders elect board, approve pay and auditor
Arcturus Therapeutics Holdings Inc. recently held its 2026 annual meeting where shareholders made key decisions. They elected eight directors to serve until the 2027 annual meeting, approved the named executive officer compensation on an advisory basis, and ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The meeting saw a high quorum with over 75% of shares entitled to vote being represented.
(ARCT) Movement Within Algorithmic Entry Frameworks
Arcturus Therapeutics Holdings Inc. (ARCT) is showing a mid-channel oscillation pattern, with near-term strong sentiment challenging persistent mid and long-term weakness. AI models have generated three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—each with specific entry, target, and stop-loss levels. The article highlights an exceptional 225.5:1 risk-reward setup, targeting a 75.0% gain versus 0.3% risk.
Is Arcturus Therapeutics Poised for a Massive Upside in 2026
Arcturus Therapeutics is drawing significant Wall Street attention due to its innovative self-amplifying mRNA platform and promising pipeline candidates, ARCT-032 for cystic fibrosis and ARCT-810 for OTC deficiency, which are nearing critical clinical and regulatory milestones in early 2026. Analysts project a potential upside of 218% to 404%, with a high target of 775% to 963%, driven by these advancements. However, investing in ARCT is considered high-risk due to the volatility inherent in biotech, relying heavily on successful clinical trial outcomes and regulatory approvals.
Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
Arcturus Therapeutics Holdings Inc. announced it will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 9:20 a.m. ET. The company, known for its mRNA medicines, focuses on liver and respiratory rare disease therapeutics and has developed the first approved self-amplifying mRNA COVID vaccine, KOSTAIVE®. A webcast of the presentation will be available on Arcturus's investor relations website.
Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
Arcturus Therapeutics Holdings Inc. announced it will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 9:20 a.m. ET. The company, a messenger RNA medicines specialist, focuses on developing therapeutics for liver and respiratory rare diseases and also manufactures vaccines. Arcturus utilizes advanced technologies like LUNAR® lipid-mediated delivery and STARR® mRNA technology.
Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
Arcturus Therapeutics Holdings Inc. announced it will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 9:20 a.m. ET. The company, which specializes in messenger RNA medicines for rare liver and respiratory diseases, will provide a webcast link on its investor relations website. Arcturus is known for its LUNAR® lipid-mediated delivery and STARR® mRNA technologies, including the development of KOSTAIVE®, the first approved self-amplifying mRNA COVID vaccine.
ARCT - Arcturus Therapeutics: Strategic opportunities beyond CSL
Arcturus Therapeutics is facing challenges with its collaboration with CSL regarding the KOSTAIVE Covid-19 vaccine, with CSL writing off $430 million related to the agreement and arbitration ongoing over milestone payments. This situation creates strategic opportunities for Arcturus to pivot towards new collaboration partners like Sanofi or BioNTech, who are looking to advance their mRNA vaccine pipelines. Despite current low investor confidence and declining revenue from the CSL agreement, Arcturus possesses valuable advanced RNA technology and a pipeline including rare disease programs, which could significantly increase its market capitalization through new partnerships.
How (ARCT) Movements Inform Risk Allocation Models
This article analyzes Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) using AI models, highlighting weak sentiment across all time horizons and an exceptional 232.5:1 risk-reward setup. It outlines three trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis for support and resistance levels. The report emphasizes the potential for a 74.3% gain against a 0.3% risk based on current signals.
Arcturus Therapeutics Holdings Inc (NQ: ARCT) News
This article provides recent news headlines concerning Arcturus Therapeutics Holdings Inc (ARCT), primarily focusing on analyst ratings and the company's stock performance and COVID-19 vaccine developments in August 2021. Key updates include positive interim results for a Phase 1 trial, an mRNA COVID-19 vaccine update, and the company receiving approval for vaccine candidates and establishing a manufacturing plant in Vietnam.
Arcturus Therapeutics Holdings Inc (NQ: ARCT)
This page provides a collection of recent news headlines and articles related to Arcturus Therapeutics Holdings Inc. (ARCT), focusing on topics such as Q4 earnings, growth investment opportunities, analyst ratings, and biotech stock performance. The articles span from July 2023 to March 2024, highlighting ARCT's financial performance, pipeline potential, and analyst insights.
HC Wainwright & Co. Maintains Arcturus Therapeutics Holdings (ARCT) Neutral Recommendation
HC Wainwright & Co. has reiterated its Neutral rating on Arcturus Therapeutics Holdings (ARCT). This indicates that the analyst firm does not foresee significant upward or downward movement for the stock in the near term. Investors often look to such ratings for an independent assessment of a company's financial health and stock potential.
HC Wainwright & Co. Maintains Arcturus Therapeutics Holdings (ARCT) Neutral Recommendation
This article reports that HC Wainwright & Co. has reiterated its Neutral rating on Arcturus Therapeutics Holdings (ARCT). The rating was maintained by analyst Joseph Pantginis. The content of the report is not provided.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Arcturus Therapeutics Holdings Inc. recently reported first-quarter results that fell short of revenue expectations, leading analysts to revise down their forecasts. The consensus for 2026 now projects a significant revenue decline to US$15.7m and increased losses of US$4.20 per share. This negative outlook has caused the consensus price target to drop by 12% to US$20.40, indicating growing pessimism about the company's intrinsic value.
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates
Arcturus Therapeutics (ARCT) reported a Q1 loss of $0.95 per share, surpassing the Zacks Consensus Estimate of a $1.14 loss, representing a 16.91% surprise. However, the company missed revenue estimates by 73.79%, posting $2.06 million against an expectation for significantly more. Despite the revenue miss, Arcturus Therapeutics' shares have risen nearly 48.9% year-to-date, outperforming the S&P 500, but its short-term outlook is a Zacks Rank #3 (Hold) due to mixed estimate revisions.
CCORF Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $21
CCORF has reiterated its Buy rating for Arcturus Therapeutics (ARCT.US) and maintained its target price of $2
Biotechnology company Arcturus Therapeutics Holdings Inc. recently announced through a filing with the U.S. Securities and Exchange Commission (SEC) that Mr. Dennis Mulroy has been officially appointed as the company's Chief Financial Officer (CFO), eff
Arcturus Therapeutics Holdings Inc., a biotechnology company, has announced the appointment of Dennis Mulroy as its new Chief Financial Officer (CFO), effective May 1, 2026. This appointment, disclosed in an SEC filing and approved by the board, signifies a strategic deployment to strengthen the company's financial management. Mulroy will oversee financial planning, capital management, investor relations, and compliance, providing crucial financial support for Arcturus's mRNA therapies and vaccine development.
ARK/ Cathie Wood report 2.95M shares in Arcturus (ARCT)
ARK Investment Management LLC and Catherine D. Wood have reported beneficial ownership of 2,947,556 shares of Arcturus Therapeutics Holdings Inc. (ARCT), representing a 10.37% stake in the company. This disclosure was made in an amended Schedule 13G/A filing with the SEC, dated May 7, 2026. ARK holds sole voting and dispositive power over these shares, while Catherine D. Wood possesses shared voting and dispositive power over the same amount.
Earnings call transcript: Arcturus Therapeutics Q1 2026: EPS Beat, Revenue Decline
Arcturus Therapeutics reported a Q1 2026 EPS beat, exceeding forecasts by 15.18% with -0.95 USD despite a revenue decline. The company is strategically shifting its focus to rare disease clinical programs, moving away from partnership income, which led to the revenue decrease. Leadership highlighted strong cash reserves extending through Q2 2028, providing financial flexibility for ongoing investments in its mRNA therapeutic pipeline.
Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress
Arcturus Therapeutics has announced its financial results for Q1 2026, alongside significant pipeline advancements in its rare disease programs. The company has initiated enrollment for a Phase 2 study of its inhaled mRNA therapeutic for Cystic Fibrosis (ARCT-032) and received FDA regulatory direction for its ornithine transcarbamylase (OTC) deficiency program (ARCT-810), securing a path toward a pivotal pediatric trial. Arcturus reports a cash position of $213.4 million, providing a runway extending beyond Q2 2028, and has strengthened its executive team with new Chief Medical and Financial Officers.
Q1 2026 Arcturus Therapeutics Holdings Inc Earnings Call Transcript
This article provides the Q1 2026 earnings call transcript for Arcturus Therapeutics Holdings Inc. The call began with an introduction by Neda Safarzadeh, Vice President, Head of Investor Relations, Public Relations and Marketing, followed by remarks from Joe Payne, President and CEO, Dr. Alan Cohen, Chief Medical Officer, and Dennis Mulroy, Chief Financial Officer. The transcript details the opening statements and the initial part of the earnings call.
Biotechnology company Arcturus Therapeutics Holdings Inc. recently announced through a filing with the U.S. Securities and Exchange Commission (SEC) that Mr. Dennis Mulroy has been officially appointed as the company's Chief Financial Officer (CFO), eff
Arcturus Therapeutics Holdings Inc., a biotechnology company, has announced the appointment of Dennis Mulroy as its new Chief Financial Officer (CFO), effective May 1, 2026. This appointment was disclosed in an SEC filing and signifies a strategic move to bolster the company's financial management. Mulroy will be responsible for financial planning, capital management, investor relations, and compliance, supporting the company's focus on mRNA therapies and vaccine development.
Arcturus Therapeutics (NASDAQ: ARCT) Q1 2026 hit by 93% revenue drop
Arcturus Therapeutics reported a significant 93% drop in Q1 2026 revenue to $2.1 million, down from $29.4 million a year earlier, primarily due to reduced collaboration revenue from CSL Seqirus and lower BARDA grant revenue. Despite the revenue decline, operating expenses decreased, narrowing the cash burn though the net loss widened to $27.0 million. The company ended the quarter with $213.4 million in cash, which is expected to fund operations for at least the next twelve months, as it continues to advance its rare-disease RNA therapeutic candidates ARCT-032 and ARCT-810.
[Form 3] Arcturus Therapeutics Holdings Inc. Initial Statement of Beneficial Ownership
Arcturus Therapeutics Holdings Inc. has filed an initial Form 3 for its Chief Financial Officer, Dennis Mulroy, establishing a baseline statement of beneficial ownership. The filing indicates no reportable transactions or derivative positions, nor any existing holdings, serving purely as a foundational declaration of ownership status for the CFO. This is a neutral filing, with no positive or negative impact on the stock mentioned.
Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress
Arcturus Therapeutics announced its Q1 2026 financial results, highlighting progress in its rare disease pipeline. Key advancements include initiating enrollment for a Phase 2 cystic fibrosis study ahead of schedule and receiving FDA guidance for its OTC deficiency program, allowing a clear path to a pivotal pediatric trial. The company also reported a strong cash position of $213.4 million, providing a cash runway extending beyond Q2 2028, and announced the appointments of a new Chief Medical Officer and Chief Financial Officer.
Revenue plunge and leadership change at Arcturus (NASDAQ: ARCT)
Arcturus Therapeutics reported a significant widening of its Q1 2026 net loss to $27.0 million from $14.1 million year-over-year, alongside a sharp revenue decline to $2.1 million from $29.4 million, as the company shifts focus from infectious disease vaccines to rare disease programs. Despite the financial setbacks, the company maintains a cash runway beyond Q2 2028 and made pipeline progress in cystic fibrosis and ornithine transcarbamylase deficiency. Additionally, Arcturus appointed Dennis Mulroy as its new Chief Financial Officer, detailing his compensation package and outlining his role in the company's financial strategy.
